The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function
Open Access
- 29 February 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Abstract
Chronic treatment with GLP-1R agonists may moderately lower blood pressure due to increased natriuresis and RAAS inhibition. Short-term effect of these drugs on blood pressure may be opposite and its mechanism remains unclear. We investigated the effect of a single dose of liraglutide on diurnal blood pressure profile, natriuresis, hydration and serum concentration of renin, aldosterone and atrial natriuretic peptide (ANP) in diabetic kidney disease (DKD). 17 patients with eGFR < 30 ml/min/1.73 m2 and 17 with > 60 ml/min/1.73 m2 received in a random order a single subcutaneous dose 1.2 mg liraglutide and placebo with subsequent 24 h blood pressure and natriuresis monitoring. Before and after each medication thoracic fluid index and plasma renin, aldosterone and ANP were also assessed. The blood pressure load in the daytime and nighttime were significantly increased after liraglutide compared to placebo in patients with eGFR < 30 ml/min/1.73 m2. In patients with eGFR > 60 ml/min/1.73 m2 the changes of arterial pressure were comparable, while the morning surge was significantly reduced after liraglutide compared to placebo. After liraglutide 24 h urine sodium excretion increased in both groups vs. placebo (p < 0.001), the effect was greatest in subjects with eGFR > 60 ml/min/1.73 m2. Plasma ANP increased after liraglutide in both groups, most in patients with eGFR < 30 ml/min/1.73 m2 group. Plasma aldosterone (p = 0.013) and thoracic fluid index (p = 0.01) decreased after liraglutide compared to placebo (p = 0.013 and p + 0.01, respectively. Plasma renin concentration remained unchanged. In severe chronic kidney disease liraglutide induces a transient increase of blood pressure due to reduced natriuresis. The natriuretic effect of liraglutide in DKD may be related to increased ANP and decreased aldosterone secretion.Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy MenThe Journal of Clinical Endocrinology & Metabolism, 2013
- Blood pressure‐lowering effects of GLP ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, Obesity and Metabolism, 2013
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- Investigation of the haemodynamic effects of exenatide in healthy male subjectsBritish Journal of Clinical Pharmacology, 2012
- Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutideBritish Journal of Clinical Pharmacology, 2009
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humansAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Global burden of blood-pressure-related disease, 2001The Lancet, 2008
- The salt paradox and its possible implications in managing hypertensive diabetic patientsCurrent Hypertension Reports, 2005
- Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese MenThe Journal of Clinical Endocrinology & Metabolism, 2004
- Renal disease and hypertension in non–insulin-dependent diabetes mellitusKidney International, 1999